INDEGENE LIMITED Fair Value
INDGN · Healthcare · Current price ₹606.3
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹165 | 14% ROE fading to 12% over ~20 yrs, on ₹130 book |
| Relative P/E | ₹1,077 | EPS × 64.7 peer-median P/E |
| Graham floor | ₹221 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹619 | Street consensus 12-month target price |
Is INDEGENE LIMITED undervalued?
DocStoX estimates the fair value of INDEGENE LIMITED at ₹464 per share, versus the current market price of ₹606. That puts the stock about -23.4% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹165), Relative P/E (₹1,077), Graham floor (₹221), Analyst target (₹619). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹165 (bear) to ₹464 (base) to ₹1,077 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on INDEGENE LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.